Connecting to LinkedIn...

W1siziisijiwmtuvmdqvmtuvmdgvntqvmzgvnzi1l01ptlrbu0hfqkxpr19vtljftkrfukvex0lnqudfx3jlc2l6zwrfyw5kx3jlbmrlcmvklmpwzyjdlfsiccisinrodw1iiiwimtkymhgxmjuwiyjdxq

Blog

Shire pharmaceutical valued at £30bn in new AbbVie bid

8/07/2014 by

W1siziisijiwmtqvmtavmjgvmtuvmzqvmdkvmzczl2zpbguixsxbinailcj0ahvtyiisijywmhg0mdbcdtawm2uixv0

Pharmaceutical company Shire has been valued at £30bn in a raised bid from the US rival which has been trying to take control of the business for weeks.

The chairman of Chicago-based AbbVie urged Shire shareholders to back its fourth offer for the FTSE 100 company, which is best known for its controversial treatment for attention deficit hyperactivity disorder.

Richard Gonzalez, who is also chief executive of AbbVie, said: “This transaction is a combination of two leading companies with leadership positions in specialty pharmaceuticals that would create a global market leader with unique characteristics and a compelling investment thesis.

“AbbVie has made a compelling offer to Shire that creates immediate and long-term value to shareholders of both companies. We think its shareholders should strongly encourage the Shire board to engage in constructive dialogue with AbbVie,” Gonzalez said.

The latest offer values each Shire share at £51.15 – above the current price of £46.30 – and is based on a mixture of cash and AbbVie shares. This compares with the £46.11 a share in the offer made public in June which prompted Shire’s boss Flemming Ørnskov to set out a plan to double sales over the next seven years in an attempt to remain independent.

Ørnskov, who has been running Shire since May 2013, set out a plea to remain independent last month even as he admitted that he could not close the door on bids.

The offer for Shire, which moved its tax base to Dublin in 2008, follows the ill-fated attempt by US pharmaceutical company Pfizer to take control of FTSE 100 company AstraZeneca.

This article has been extracted from http://www.theguardian.com, please click on this link to read the article in full http://www.theguardian.com/business/2014/jul/08/shire-pharmaceutical-30bn-new-abbvie-bid

Montash is a multi-award winning, global IT recruitment firm. Specialising in permanent and contract positions across mid-senior appointments which cover a wide range of industry sectors and IT functions, including:

ERP, BI & Data, Information Security, IT Architecture & Strategy, Scientific Technologies, Demand IT and Business Engagement, Digital and E-commerce, Infrastructure and Service Delivery, Project and Programme Delivery.

With offices based in London, Montash has completed assignments in over 30 countries and has appointed technical professionals from board level to senior and mid-management in permanent and contract roles.

comments powered by Disqus

Social Stream

Latest News

W1siziisijiwmtcvmdevmtgvmdkvmtqvmzmvmzk5l0vsuc5qcgcixsxbinailcj0ahvtyiisijm4mhgxmdajil1d

Sage bolsters X3 business ERP solution

2017-01-18 09:00:00 +0000

Sage, one of the global leaders in enterprise resource planning (ERP) solutions, has revealed that it has signed up a trio of new clients to its X3 business solution. With the Salesforce.com partner wanting to be able to show its ability to host larger clients, the firm revealed that BrightBridge, Atlas Cloud and CLOUT are all now utilising the new and emerging X3 ERP platform. Sage Vice President of UK Enterprise David Watts talked about the latest agr...

W1siziisijiwmtcvmdevmtcvmtavmzcvmzevmjq2l0nsb3vkighlywx0agnhcmuuanbnil0swyjwiiwidgh1bwiilcizodb4mtawiyjdxq

Cloud computing making its mark in healthcare

2017-01-17 10:00:00 +0000

The cloud computing sector has grown quickly, and businesses in various sectors have been quick to take advantage of its many benefits to improve services. One such market is the healthcare industry, which has been able to improve diagnosing and enhance treatment methodologies as a result of new technologies over the past decade. Cloud technology is helping one area in particular – the healthcare of people living in remote locations who would not ordina...